Company Overview and News

3
Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors

2018-09-13 globenewswire
CAMBRIDGE, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran brings to Solid more than 30 years of experience in key functional areas, including gene therapy development, clinical strategy, medical affairs and diagnostics.
AVXS SLDB DGX RETA

6
Novartis's Cultural Revolution Will Be AI-Enabled and Desk-Free - Bloomberg

2018-07-24 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AVXS BOE NVS GSK BA GSK

11
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

2018-07-18 globenewswire
"We made significant progress this quarter to transform Novartis into a focused medicines company. We completed the Alcon strategic review, exited the OTC joint venture, and strengthened our innovation engine with the acquisition of AveXis. Operationally we delivered solid growth, with margins expanding and key growth drivers including Cosentyx delivering strong performance. We also advanced our transformational medicines portfolio as we launched Kymriah in DLBCL and Aimovig in the US, completed the regulatory submission of BAF312 to FDA, and progressed toward a submission of our gene therapy AVXS-101.
CZMWF AVXS CZMWY NVS ABBV ABBV

79
PTC Therapeutics Surges On Positive Outcome From Rare Disease Study

2018-06-19 seekingalpha
PTC Therapeutic's stock soars on positive phase 1 results treating patients with a rare muscle wasting disease known as spinal muscular atrophy.
AVXS BIIB IONS NVS PTCT

13
AVXS / AveXis, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-06-11 sec.gov
SCHEDULE 13G Amendment No. 4 AVEXIS INC COMMON STOCK Cusip #05366U100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05366U100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000 % Item 12: HC Cusip #05366U100 Item 1: Reporting Person - Abigail P.
AVXS

14
AVXS / AveXis, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-06-11 sec.gov - 1
SCHEDULE 13G Amendment No. 4 AVEXIS INC COMMON STOCK Cusip #05366U100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05366U100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000 % Item 12: HC Cusip #05366U100 Item 1: Reporting Person - Abigail P.
AVXS

13
AVXS / AveXis, Inc. null

2018-06-06 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
AVXS

13
AVXS / AveXis, Inc. 15-12B

2018-06-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AVXS

165
Crispr On Hold While Sangamo Accelerates

2018-06-04 seekingalpha - 3
The gene editing group relying on Crispr was negatively impacted by the FDA hold on CTX001 last week.
NTLA AVXS CRSP ABEO ONCE RGNX VYGR BOLD EDIT CELG NVS BLUE ABEOW PFE

481
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha - 7
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high.
ECYT AVXS GTHX LOXO ARNA ATRA IMMU BIIB CELG HRTX ADAP REGN AMGN GILD NBIX CRSP SRPT ARIA SUPN SNY CBIO JNJ MRTX NVS BGNE IRR CLSD PFE

102
U.S. IPO Weekly Recap: Payment IPOs Pay Off As 6 Deals Price Ahead Of Memorial Day

2018-05-27 seekingalpha
The average return for 2018 IPOs remained at about 23%. YTD IPOs have averaged a +13% first-day gain and +8% in the aftermarket. Currently, 68% of the year's 75 IPOs trade above issue. This past week, markets ticked slightly higher: Our IPO Index was up 0.3%, while the S&P 500 gained 0.5%. The VIX Volatility Index remained comfortably below 15.
ITRM SPRO AVXS GSKY SPOT MLNT EVOP SNAP IFRX

14
AVXS / AveXis, Inc. / Adage Capital Partners GP LLC - AVEXIS, INC. (Activist Investment)

2018-05-17 sec.gov - 1
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AVXS

14
AVXS / AveXis, Inc. / Adage Capital Partners GP LLC - AVEXIS, INC. (Activist Investment)

2018-05-17 sec.gov - 1
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AVXS

99
Bluebird Bio: Gene Therapy Best In Class

2018-05-16 seekingalpha - 3
The current quarterly cash burn remains modest leaving most of the group with enough capital to operate through 3 to 5 years.
NTLA AVXS BLUE CRSP ABEO ONCE RGNX VYGR BOLD EDIT BLUE ABEOW

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 05366U100